Key facts
- This page summarizes Alan A. Ades's Form 4 filing for Organogenesis Holdings Inc. (ORGO).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2025, 17:03.
Alan A. Ades - 09 Jan 2025 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ORGO
- Reported as of
- 09 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 17:03:54 UTC
- Prior SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Kolb, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alan A. Ades filed Form 4 for Organogenesis Holdings Inc. (ORGO) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORGO
transaction
Class A Common Stock
Gift
- Transaction value
- $0
- Shares
- -6,401,945
- Change %
- -11%
- Price
- $0.000000
- Shares after
- 51,085,402
- Date
- 09 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ORGO
transaction
Class A Common Stock
Gift
- Transaction value
- $0
- Shares
- +6,401,945
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 51,085,402
- Date
- 09 Jan 2025
- Ownership
- By spouse
- Footnotes
- F1, F2
ORGO
transaction
Class A Common Stock
Gift
- Transaction value
- $0
- Shares
- +6,401,945
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 51,085,402
- Date
- 09 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities.
Footnote F2
Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group.
SEC remarks
Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016, GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, RED Holdings, LLC and Josette Ades, referred to collectively as the "Group", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Group with respect to four directors of the Issuer. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 4 No. 2 of 2 filed for the Group.